Brookfield acquires Antylia Scientific for $1.4 billion - FT

Published 02/04/2025, 22:06
© Reuters.

Brookfield, a global alternative asset manager, has agreed to purchase Antylia Scientific, a specialist in laboratory equipment, for $1.4 billion, according to Financial Times, citing sources familiar with the matter. This acquisition marks the end of GTCR’s intermittent ownership of the company over the past decade. GTCR initially separated Antylia from the larger Thermo Fisher Scientific (NYSE:TMO) in 2014.

The transaction, which also involves Antylia’s minority stakeholders Golden Gate Capital and the management team, was finalized in the preceding weeks. The announcement of the deal is anticipated soon, barring any unforeseen complications.

Goldman Sachs and Jefferies provided financial advice for the sale, underscoring the significance of the transaction in the private capital market. The acquisition of Antylia Scientific by Brookfield indicates a strategic expansion within the laboratory equipment sector.

Antylia Scientific has established a reputation for providing critical tools and services for the life sciences industry. The deal with Brookfield is expected to provide the company with a robust platform for future growth and expansion.

The acquisition is part of a broader trend of investment firms showing keen interest in the life sciences sector, which has seen a surge in demand partly due to the global health challenges and advancements in biotechnology.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.